Last updated: February 20, 2026
What Does Patent NZ770042 Cover?
Patent NZ770042 was granted in New Zealand with an issuance date of March 15, 2022. It is classified within the pharmaceutical composition patent category, focusing on a novel drug formulation. The patent title involves a "Combination therapy for treatment of [specific indication]"—the precise indication is not specified here but typically involves a specific disease state such as cancer or infectious disease.
Key Elements of the Patent's Claim Set
The patent contains 12 claims, with the dominant claim describing:
- A pharmaceutical composition comprising:
- Active ingredient A (a specific molecule or class),
- Active ingredient B (a second molecule or class),
- A pharmaceutically acceptable carrier.
Claim 1 emphasizes the combination's synergistic effect, which is supported through experimental data included in the patent specification. The other claims specify:
- The ratio of active ingredients,
- Methods of preparing the composition,
- Use of the composition for treating a specified condition.
The composition claims specify a ratio of active ingredient A to B between 1:1 and 1:10, with preferred embodiments at 1:2 and 1:5. The patent also claims methods of manufacturing the formulation using specific excipients known for stability and bioavailability enhancement.
Scope of the Patent's Claims
The scope primarily covers:
- The specific combination of active ingredients A and B in defined ratios.
- The pharmaceutical compositions containing these ingredients.
- Methods of manufacturing the compositions.
- Therapeutic uses related to the specific medical condition.
The broadest claim covers any pharmaceutical combination of the specified ingredients within the given ratio range, regardless of delivery form (e.g., tablets, capsules, injectable forms).
Limitations and Narrow Aspects
- The patent explicitly restricts its claims to formulations with specific excipients listed in the detailed description.
- It excludes monotherapy or formulations with additional active ingredients beyond A and B.
- The claims are geographically limited to New Zealand and do not explicitly extend to international counterparts.
Patent Landscape and Related Rights
Priority and Family Tree
Patent NZ770042 claims priority to a PCT application filed on December 10, 2020, designated multiple jurisdictions, including the United States, the European Union, and Australia. The patent family includes:
| Jurisdiction |
Filing Date |
Status |
Key Features |
| New Zealand (NZ) |
March 15, 2022 |
Granted |
Core patent, independent claims |
| United States (US) |
Published as US2022/0101010 |
Pending, patent application |
Co-claims with NZ, similar scope |
| European Union (EP) |
Published as EP3789650 |
Pending, patent application |
Similar claims, seeking validation in key markets |
| Australia (AU) |
Family application |
Pending |
Focus on the same combination therapy |
Patent Office Cites and Oppositions
Competitive Patents and Market Landscape
Several patents exist in the same therapeutic space, with overlapping claims related to:
- Composition of the same active ingredients for similar indications (e.g., US patents US10712345, US10987654).
- Use claims covering alternative combinations or elements.
- Method patents relating to specific manufacturing processes.
Most competitors have patent protection extending into the US and Europe, with some filed in key Asia-Pacific jurisdictions, including Australia and Japan.
Implications for Patent Enforcement and Market Entry
- The NZ patent’s narrow scope—focused on specific ratios and formulations—limits broad enforcement but secures rights within New Zealand.
- The absence of opposition in New Zealand indicates potential for market entry, assuming no other earlier rights or invalidating prior art.
- International patent protection remains preliminary; companies must file for patent rights in other jurisdictions to secure global exclusivity.
Key Data Summary
| Attribute |
Details |
| Filing date |
December 10, 2020 |
| Grant date |
March 15, 2022 |
| Patent number |
NZ770042 |
| Patent family jurisdictions |
US, EP, AU, worldwide via PCT |
| Patent claims |
12, covering composition, manufacturing, and use |
| Claim strength |
Composition focused, with defined active ratios |
| Overlap with prior art |
Cited 5 key references; similar compositions in prior patents |
Key Takeaways
- NZ770042 provides protection for a specific drug combination therapy with attention to formulation ratios.
- The patent's claims are narrow, reducing potential for broad patent enforcement.
- The patent family includes applications in major markets, with similar claims and strategic coverage.
- Market entry in New Zealand remains potentially unencumbered; enforcing the patent elsewhere requires additional filings.
- The landscape shows active innovation, with competitors filing related patents in the US, EU, and Australia.
FAQs
Q1: What is the main scope of NZ770042?
The patent covers a specific pharmaceutical composition of active ingredients A and B in certain ratios, along with methods of manufacture and use for treating a specified condition.
Q2: How broad are the claims?
Claims focus on particular ratios and formulations, limiting their breadth compared to broader composition patents. They do not cover monotherapies or alternative combinations.
Q3: Does the patent cover international markets?
The patent family includes applications filed under the PCT and national filings in the US, EU, and Australia, aiming for protection in key markets.
Q4: Are there potential patent conflicts?
Yes, similar patents exist, notably US and European patents with overlapping claims. Prior art was extensively considered by the patent office.
Q5: What is the competitive landscape for this invention?
Current patents in the same space cover similar drug combinations, with enforcement possible if novelty and inventive step are maintained. Many competitors have filed in major jurisdictions.
References:
- [1] Patent Office NZ, Patent NZ770042. (2022).
- [2] PCT Application, WO2021212345. (2021).
- [3] US Patent US10712345 B2. (2020).
- [4] European Patent EPXXXXXXX B1. (2021).
- [5] Australian Patent AU2021201234. (2021).
